Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Cynthia Firnhaber

Concepts (280)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Uterine Cervical Dysplasia
16
2024
43
5.940
 Why?
Uterine Cervical Neoplasms
21
2024
234
5.620
 Why?
HIV Infections
48
2025
2721
4.550
 Why?
Papillomavirus Infections
18
2024
291
4.120
 Why?
South Africa
40
2021
192
3.150
 Why?
Papillomaviridae
11
2022
113
2.560
 Why?
Papanicolaou Test
7
2024
43
1.850
 Why?
HIV Seropositivity
8
2017
120
1.660
 Why?
Early Detection of Cancer
8
2024
350
1.640
 Why?
Alphapapillomavirus
2
2022
40
1.540
 Why?
Papillomavirus Vaccines
5
2021
230
1.510
 Why?
Tuberculosis, Multidrug-Resistant
9
2019
57
1.400
 Why?
Colposcopy
4
2024
16
1.300
 Why?
Acquired Immunodeficiency Syndrome
4
2022
226
1.200
 Why?
Antiretroviral Therapy, Highly Active
7
2020
267
1.170
 Why?
Cryotherapy
2
2017
16
1.130
 Why?
Breast Neoplasms
5
2024
2139
1.110
 Why?
Quality Assurance, Health Care
5
2017
320
1.100
 Why?
Rifampin
9
2021
83
1.100
 Why?
Vaginal Smears
5
2024
56
1.080
 Why?
Optical Imaging
2
2015
56
0.920
 Why?
Antitubercular Agents
7
2021
197
0.920
 Why?
HIV-1
12
2020
843
0.900
 Why?
Anti-HIV Agents
12
2020
750
0.840
 Why?
Mammography
1
2024
139
0.820
 Why?
Adult
50
2025
35711
0.780
 Why?
Delayed Diagnosis
2
2019
81
0.760
 Why?
Molecular Diagnostic Techniques
3
2017
95
0.710
 Why?
Antibiotics, Antitubercular
3
2019
37
0.710
 Why?
Female
61
2025
68842
0.690
 Why?
CD4 Lymphocyte Count
11
2018
269
0.610
 Why?
Cost-Benefit Analysis
5
2018
621
0.600
 Why?
Access to Information
1
2018
48
0.590
 Why?
Carcinoma, Ductal, Breast
1
2018
82
0.590
 Why?
Hepatitis B
2
2008
62
0.580
 Why?
Breast
1
2018
152
0.580
 Why?
Contraceptive Agents, Female
2
2020
78
0.570
 Why?
Antibodies, Viral
4
2018
607
0.560
 Why?
Coinfection
6
2024
130
0.550
 Why?
Oncology Service, Hospital
1
2017
16
0.550
 Why?
Patient Acceptance of Health Care
2
2024
771
0.540
 Why?
Electrosurgery
1
2017
43
0.540
 Why?
Prevalence
13
2018
2576
0.540
 Why?
Ambulatory Care Facilities
2
2017
227
0.530
 Why?
Anus Neoplasms
2
2015
30
0.520
 Why?
Humans
68
2025
130305
0.520
 Why?
Mass Screening
7
2025
1139
0.520
 Why?
Trichomonas vaginalis
2
2012
13
0.500
 Why?
Health Resources
1
2017
122
0.500
 Why?
Middle Aged
28
2025
31322
0.500
 Why?
Tuberculosis
5
2021
273
0.490
 Why?
Surgical Instruments
1
2015
53
0.490
 Why?
Women's Health Services
1
2015
16
0.480
 Why?
Mobile Health Units
1
2015
21
0.480
 Why?
Reverse Transcriptase Inhibitors
1
2015
82
0.470
 Why?
Viral Load
8
2020
452
0.470
 Why?
Specimen Handling
1
2015
166
0.460
 Why?
Precancerous Conditions
4
2020
165
0.450
 Why?
Health Services Accessibility
2
2019
902
0.450
 Why?
Rural Health Services
1
2015
110
0.440
 Why?
Urban Population
3
2018
439
0.430
 Why?
Genital Neoplasms, Male
1
2012
5
0.410
 Why?
Mycoplasma genitalium
1
2012
2
0.400
 Why?
Urethritis
1
2012
3
0.400
 Why?
Anti-Retroviral Agents
5
2021
230
0.400
 Why?
Uterine Cervicitis
1
2012
7
0.400
 Why?
Neisseria gonorrhoeae
1
2012
22
0.400
 Why?
HIV
3
2022
225
0.390
 Why?
Chlamydia trachomatis
1
2012
45
0.390
 Why?
Oropharyngeal Neoplasms
1
2012
48
0.390
 Why?
Hepatitis B Surface Antigens
2
2008
19
0.390
 Why?
Pregnancy Complications, Infectious
1
2016
336
0.390
 Why?
Carcinoma, Squamous Cell
2
2017
628
0.370
 Why?
Sensitivity and Specificity
7
2017
1854
0.370
 Why?
AIDS-Related Opportunistic Infections
1
2012
124
0.370
 Why?
Genital Neoplasms, Female
1
2012
81
0.370
 Why?
Cervix Uteri
3
2024
50
0.370
 Why?
Condylomata Acuminata
1
2011
7
0.370
 Why?
Penile Diseases
1
2011
5
0.370
 Why?
Protease Inhibitors
1
2011
105
0.350
 Why?
Neutropenia
1
2010
135
0.330
 Why?
Health Knowledge, Attitudes, Practice
1
2018
1272
0.330
 Why?
Anemia
1
2010
156
0.320
 Why?
Sexually Transmitted Diseases
2
2025
146
0.310
 Why?
Thrombocytopenia
1
2010
188
0.300
 Why?
Diarylquinolines
2
2018
12
0.300
 Why?
Health Care Costs
4
2018
407
0.290
 Why?
Delivery of Health Care
1
2015
906
0.290
 Why?
Anal Canal
2
2018
89
0.280
 Why?
Women's Health
1
2009
362
0.270
 Why?
DNA, Viral
3
2018
384
0.260
 Why?
Young Adult
15
2018
12404
0.260
 Why?
Disease Progression
4
2016
2639
0.260
 Why?
Human Papillomavirus DNA Tests
2
2017
3
0.260
 Why?
Acetic Acid
2
2016
16
0.250
 Why?
Atazanavir Sulfate
2
2016
41
0.250
 Why?
Antineoplastic Agents
1
2017
2078
0.250
 Why?
Neoplasm Staging
2
2019
1294
0.240
 Why?
Treatment Outcome
10
2024
10341
0.230
 Why?
Prospective Studies
7
2019
7131
0.230
 Why?
Health Status
1
2009
756
0.230
 Why?
Tenofovir
2
2017
231
0.230
 Why?
Medroxyprogesterone Acetate
2
2021
35
0.230
 Why?
Adolescent
13
2022
20374
0.230
 Why?
Developing Countries
4
2018
278
0.220
 Why?
Drug Resistance, Bacterial
2
2016
171
0.220
 Why?
Laboratories
2
2015
104
0.220
 Why?
Lamivudine
2
2015
61
0.210
 Why?
Zidovudine
2
2015
78
0.210
 Why?
Male
23
2025
63748
0.210
 Why?
Comorbidity
3
2016
1555
0.200
 Why?
Cytochrome P-450 CYP3A Inducers
1
2021
5
0.190
 Why?
Vaccination
3
2021
1361
0.190
 Why?
Cytochrome P-450 CYP3A Inhibitors
1
2021
20
0.180
 Why?
Retrospective Studies
8
2021
14675
0.180
 Why?
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
2
2018
15
0.180
 Why?
Aged
8
2019
22282
0.180
 Why?
Human papillomavirus 18
2
2011
15
0.180
 Why?
United States
8
2025
14110
0.180
 Why?
Cytochrome P-450 CYP3A
1
2021
67
0.180
 Why?
Outpatients
1
2024
369
0.180
 Why?
Human papillomavirus 16
2
2011
33
0.180
 Why?
Risk Factors
7
2017
9865
0.170
 Why?
Glycomics
1
2020
7
0.170
 Why?
Drug-Related Side Effects and Adverse Reactions
3
2018
260
0.170
 Why?
Incidence
4
2017
2657
0.170
 Why?
Benzoxazines
2
2021
31
0.170
 Why?
Mycobacterium tuberculosis
3
2019
316
0.170
 Why?
Cyclopropanes
2
2021
88
0.170
 Why?
Nucleic Acid Amplification Techniques
2
2019
36
0.170
 Why?
Alkynes
2
2021
54
0.170
 Why?
Lopinavir
3
2021
30
0.160
 Why?
Africa
3
2020
96
0.160
 Why?
Africa, Southern
2
2016
8
0.160
 Why?
Ritonavir
3
2021
72
0.160
 Why?
Urban Health Services
1
2019
61
0.160
 Why?
Drug Combinations
2
2021
328
0.150
 Why?
Brazil
3
2016
104
0.150
 Why?
Neoplasm Recurrence, Local
2
2021
959
0.150
 Why?
South America
3
2016
56
0.150
 Why?
Anus Diseases
1
2017
7
0.140
 Why?
Uterus
1
2018
205
0.140
 Why?
Income
1
2018
193
0.140
 Why?
Herpesvirus 2, Human
1
2017
29
0.140
 Why?
Health Care Surveys
1
2019
564
0.140
 Why?
CD4-Positive T-Lymphocytes
3
2012
1056
0.130
 Why?
Atypical Squamous Cells of the Cervix
1
2016
1
0.130
 Why?
Herpes Simplex
1
2017
94
0.130
 Why?
Neoplasm Grading
1
2017
282
0.130
 Why?
Cross-Sectional Studies
5
2019
5083
0.130
 Why?
Cytisus
1
2015
1
0.130
 Why?
Cost of Illness
1
2018
292
0.130
 Why?
Tertiary Care Centers
1
2017
147
0.130
 Why?
Mental Status and Dementia Tests
1
2016
23
0.130
 Why?
Longitudinal Studies
2
2014
2691
0.130
 Why?
Sex Factors
3
2018
1965
0.120
 Why?
Menopause
1
2018
303
0.120
 Why?
Staining and Labeling
1
2016
143
0.120
 Why?
Sputum
2
2016
309
0.120
 Why?
Asia
2
2016
58
0.120
 Why?
Stavudine
2
2012
8
0.120
 Why?
Models, Theoretical
1
2018
553
0.120
 Why?
Tuberculosis, Pulmonary
1
2016
137
0.120
 Why?
Antibodies, Neutralizing
2
2018
261
0.120
 Why?
Socioeconomic Factors
1
2019
1200
0.120
 Why?
Pre-Exposure Prophylaxis
1
2017
202
0.110
 Why?
Pharmacogenetics
1
2016
171
0.110
 Why?
Clinical Trials as Topic
2
2017
1015
0.110
 Why?
Contraception
1
2016
142
0.110
 Why?
Costs and Cost Analysis
1
2015
213
0.110
 Why?
Emtricitabine
1
2015
168
0.110
 Why?
Health Services Needs and Demand
1
2016
260
0.110
 Why?
Gene Expression
1
2019
1487
0.110
 Why?
Markov Chains
3
2018
126
0.110
 Why?
Bacteriological Techniques
1
2014
70
0.110
 Why?
RNA, Viral
2
2020
624
0.100
 Why?
Time Factors
4
2018
6615
0.100
 Why?
Trichomonas Vaginitis
1
2012
4
0.100
 Why?
Antiprotozoal Agents
1
2012
13
0.100
 Why?
Metronidazole
1
2012
20
0.100
 Why?
Virus Shedding
1
2012
44
0.100
 Why?
Age Factors
3
2018
3153
0.100
 Why?
Mycobacterium
1
2014
111
0.100
 Why?
Follow-Up Studies
3
2017
4961
0.100
 Why?
Demography
1
2013
281
0.100
 Why?
Human papillomavirus 6
1
2011
2
0.100
 Why?
Human papillomavirus 11
1
2011
2
0.100
 Why?
Botswana
1
2011
8
0.100
 Why?
Evidence-Based Medicine
1
2016
733
0.090
 Why?
Internationality
1
2012
150
0.090
 Why?
Vaginosis, Bacterial
1
2011
13
0.090
 Why?
Antigens, Viral
1
2012
181
0.090
 Why?
Immunity, Humoral
1
2012
121
0.090
 Why?
Molecular Typing
1
2011
18
0.090
 Why?
Seroepidemiologic Studies
1
2011
158
0.090
 Why?
Lipid Metabolism
2
2011
496
0.090
 Why?
Antiviral Agents
1
2017
719
0.090
 Why?
Americas
1
2010
19
0.090
 Why?
Caribbean Region
1
2010
22
0.090
 Why?
Sexual Partners
1
2012
181
0.090
 Why?
Vagina
1
2012
175
0.090
 Why?
Cohort Studies
5
2025
5431
0.090
 Why?
Prognosis
3
2020
3830
0.080
 Why?
Reflex Sympathetic Dystrophy
1
2009
6
0.080
 Why?
Delayed-Action Preparations
2
2021
179
0.080
 Why?
Health Personnel
1
2016
649
0.080
 Why?
Pregnancy
3
2020
6301
0.080
 Why?
Autoantigens
1
2012
417
0.080
 Why?
Polymerase Chain Reaction
1
2012
1051
0.080
 Why?
Leptin
1
2010
218
0.080
 Why?
Mycobacterium Infections, Nontuberculous
1
2014
377
0.080
 Why?
Cognition
1
2016
1110
0.070
 Why?
Biopsy
2
2024
1107
0.070
 Why?
Drug Costs
2
2018
111
0.070
 Why?
Adiposity
1
2011
507
0.070
 Why?
Surveys and Questionnaires
1
2018
5400
0.060
 Why?
Genotype
1
2011
1839
0.060
 Why?
Drug Administration Schedule
2
2021
766
0.060
 Why?
Reproducibility of Results
1
2013
3069
0.060
 Why?
Syphilis
1
2025
31
0.060
 Why?
Algorithms
1
2012
1638
0.060
 Why?
Primary Health Care
1
2015
1677
0.060
 Why?
Gonorrhea
1
2025
55
0.060
 Why?
Chlamydia Infections
1
2025
72
0.060
 Why?
Proportional Hazards Models
2
2017
1235
0.060
 Why?
Contraceptive Effectiveness
1
2021
1
0.050
 Why?
Nelfinavir
1
2021
8
0.050
 Why?
Isoniazid
1
2021
59
0.050
 Why?
Liver
1
2008
1846
0.040
 Why?
Randomized Controlled Trials as Topic
2
2018
1381
0.040
 Why?
Reference Standards
1
2020
171
0.040
 Why?
Drug Interactions
1
2021
370
0.040
 Why?
Meta-Analysis as Topic
1
2020
166
0.040
 Why?
Risk Assessment
1
2008
3310
0.040
 Why?
Ethiopia
1
2018
35
0.040
 Why?
Atrophy
1
2018
172
0.040
 Why?
Quality-Adjusted Life Years
1
2018
118
0.040
 Why?
Squamous Intraepithelial Lesions of the Cervix
1
2017
4
0.040
 Why?
Global Health
1
2020
320
0.040
 Why?
Proctoscopy
1
2017
5
0.040
 Why?
Microbial Sensitivity Tests
1
2019
351
0.040
 Why?
Cytodiagnosis
1
2017
32
0.040
 Why?
Virus Replication
1
2020
450
0.030
 Why?
Seroconversion
1
2017
46
0.030
 Why?
Observational Studies as Topic
1
2017
109
0.030
 Why?
Child
2
2016
20961
0.030
 Why?
Employment
1
2018
166
0.030
 Why?
International Cooperation
1
2017
174
0.030
 Why?
Pandemics
1
2025
1538
0.030
 Why?
Immunologic Memory
1
2018
340
0.030
 Why?
Peru
1
2016
54
0.030
 Why?
HIV Protease Inhibitors
1
2016
63
0.030
 Why?
Immunocompromised Host
1
2017
199
0.030
 Why?
Verbal Learning
1
2016
64
0.030
 Why?
Healthy Volunteers
1
2016
204
0.030
 Why?
DNA, Bacterial
1
2016
325
0.030
 Why?
Reference Values
1
2016
793
0.030
 Why?
Pathology
1
2013
15
0.030
 Why?
Clinical Trials, Phase II as Topic
1
2013
72
0.030
 Why?
Educational Status
1
2016
467
0.030
 Why?
National Institutes of Health (U.S.)
1
2013
123
0.030
 Why?
Polymorphism, Genetic
1
2016
643
0.030
 Why?
Africa South of the Sahara
1
2012
38
0.030
 Why?
Withholding Treatment
1
2012
69
0.020
 Why?
Gene Expression Profiling
1
2019
1714
0.020
 Why?
Medication Adherence
1
2017
577
0.020
 Why?
Serum
1
2011
57
0.020
 Why?
Cognitive Dysfunction
1
2016
346
0.020
 Why?
Body Fat Distribution
1
2010
49
0.020
 Why?
Absorptiometry, Photon
1
2011
250
0.020
 Why?
Drug Therapy, Combination
1
2012
1028
0.020
 Why?
Biomarkers
1
2020
3923
0.020
 Why?
Prednisone
1
2009
241
0.020
 Why?
Lymphocyte Activation
1
2012
1101
0.020
 Why?
Flow Cytometry
1
2011
1158
0.020
 Why?
Physical Therapy Modalities
1
2009
293
0.020
 Why?
Anti-Inflammatory Agents
1
2009
475
0.020
 Why?
Glucose
1
2010
989
0.020
 Why?
Mutation
1
2016
3723
0.010
 Why?
Magnetic Resonance Imaging
1
2011
3380
0.010
 Why?
Firnhaber's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (280) concept(s)
_
Co-Authors Expand Description
See all (5) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)